Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073201 | 0.88 | POLB (0.76) | KMT2APOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12305550 | 0.85 | KMT2A (0.62) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL30690828 | 0.82 | NPSR1 (0.64) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL27277527 | 0.82 | NPSR1 (0.64) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL12376590 | 0.82 | MEN1 (0.75) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL19175628 | 0.81 | NPSR1 (0.65) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL7978285 | 0.81 | NPSR1 (0.65) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL10202448 | 0.80 | MEN1 (0.77) | KMT2AMEN1NPSR1POLBCYP1A2 | |
| SCHEMBL14924433 | 0.79 | SMN1; SMN2 (0.70) | KMT2ANPSR1POLBCYP1A2CYP2D6 | |
| SCHEMBL20073521 | 0.79 | HPGD (0.53) | KMT2APOLBHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | BRANDEIS UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K5 | KMT2A 1776/4885MEN1 2205/4885NPSR1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.